Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma.
Shawn L Hervey-JumperYalan ZhangJoanna J PhillipsRamin A MorshedJacob S YoungLucie McCoyMarisa LafontaineTracy LuksSimon AmmanuelSofia KakaizadaAndrew EgladyousAndrew GogosJavier E Villanueva-MeyerAnny ShaiGayathri WarrierTerri RiceJason C CraneMargaret WrenschJohn K WienckeMariza DarasNancy Ann Oberheim BushJennie W TaylorNicholas A ButowskiJennifer ClarkeSusan ChangEdward F ChangManish AghiPhilip TheodosopoulosMichael McDermottAsgeir Store JakolaVasileios K KavouridisNoah NawabiOle Skeidsvoll SolheimTimothy SmithMitchel S BergerAnnette M MolinaroPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Across both subtypes of LGG, EOR beginning at 75% improves OS while beginning at 80% improves progression-free survival. Nonetheless, maximal resection with preservation of neurological function remains the treatment goal. Our findings have implications for surgical strategies for LGGs, particularly oligodendroglioma.